DSM, AC Immune Partner on AD Antibody

DSM Biologics and AC Immune SA have signed a Memorandum of Understanding in which the parties have agreed that DSM will be the development and manufacturing partner for AC Immune’s monoclonal antibody against Alzheimer’s disease. The development and manufacturing activities will be done in DSM Biologics’ FDA-approved manufacturing facility in Groningen, The Netherlands. AC Immune is based in Lausanne, Switzerland.

“After an intensive market analysis we have decided to choose DSM as our partner for the production of AC Immune’s conformation-specific monoclonal Alzheimer’s antibody, ACI-01-Ab7, based on the best quality to cost offerings by DSM,” said Andrea Pfeifer, chief executive officer of AC Immune.

“DSM Biologics is very exited to contribute to the development of AC Immune’s promising drug for treating Alzheimer’s disease and is looking forward to the mutually beneficial collaboration,” said Terry Novak, chief marketing officer, DSM Pharmaceutical Products.